Nachrichten zur Alvotech SA Aktie

Alvotech files Annual Report with the SEC

REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for…

Alvotech Publishes 2025 Annual Report

REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is…

Alvotech reports Q4 results

…

Alvotech Q4 2025 and Full Year 2025 Financial Results

A supplemental long?form earnings release providing additional operational details and business update for Q4 2025 and the full year is…

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

Alvotech: Why FDA Delays Dont Break The Bull Case

…

Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript

…

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

Bragar Eagel & Squire, P.C. Continues Investigations into Regencell, Beyond Meat, Alvotech, and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and…

Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?

ALVOs partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.…

Wall Street Analysts See a 91.05% Upside in Alvotech (ALVO): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 91.1% in Alvotech (ALVO). While…

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Alvotech has appointed Linda Jónsdóttir as its new Chief Financial Officer.…

GNW-News: Alvotech erweitert seine Kapazitäten in den Bereichen Montage und Verpackung mit der Akquisition von Ivers-Lee in der Schweiz

^REYKJAVIK, ISLAND UND BURGDORF, SCHWEIZ (9. JULI 2025) - Alvotech (NASDAQ: ALVO), ein globales Biotech-Unternehmen, das sich…

GNW-News: Alvotech erweitert seine Kapazitäten in den Bereichen Montage und Verpackung mit der Akquisition von Ivers-Lee in der Schweiz

^REYKJAVIK, ISLAND UND BURGDORF, SCHWEIZ (9. JULI 2025) - Alvotech (NASDAQ:ALVO), ein globales Biotech-Unternehmen, das sich auf die Entwicklung undHerstellung…

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

REYKJAVIK, ICELAND AND BURGDORF, SWITZERLAND (JULY 9, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and…

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Alvotech acquires capability and added flexibility in assembly and packaging with acquisition of Ivers-Lee Group…

Granting of Stock Options and Vesting of Restricted Share Units

In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company’s Annual General Meeting (“AGM”)…

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for…

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for…

Wall Street Analysts Think Alvotech (ALVO) Could Surge 72.61%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 72.6% in Alvotech (ALVO). While…

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per…

Alvotech Annual General Meeting to be held June 25, 2025

The Annual General Meeting of Alvotech will be held on Wednesday June 25, 2025, at 09.00 a.m. CEST at the…

Alvotech shares surge 6.6% as Q1 results top estimates By Investing.com

Alvotech shares surge 6.6% as Q1 results top estimates…

Alvotech (ALVO) Q4 2024 Earnings Call Transcript

…

Alvotech Reports Record Results for 2024 and Provides Business Update

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for…

Alvotech Reports Record Results for 2024 and Provides Business Update

REYKJAVIK, Iceland, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company…

FDA Accepts RDY & ALVOs Prolia & Xgeva Biosimilar BLA for Review

Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgens Prolia and…

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company…

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company…

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

REYKJAVIK, Iceland, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the…

Alvotechs Position In The Coming Biosimilar Gold Rush

…

Alvotech (ALVO) Q3 2024 Earnings Call Transcript

…

Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates

Alvotech (ALVO) delivered earnings and revenue surprises of 226.67% and 5.63%, respectively, for the quarter ended September 2024. Do the…

Alvotech application for Prolia/Xgeva biosimilar accepted by EMA

…

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced…

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces…

Alvotech (ALVO) Q2 2024 Earnings Call Transcript

…

Alvotech 2024 Q2 - Results - Earnings Call Presentation

…

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for…

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and…

dpa-AFX ProFeed